| abstract |
The present invention generally belongs to the field of therapeutic compounds. More specifically, the present invention generally pertains to certain compounds (8-azabicyclo [3.2.l] oct-8-yl) - [5- (1 H -pyrazol-4-yl) -thiophene-3-yl] -methanon a 3, 3-disubstituted, (6-aza-bicyclo [3.1.1] hept-6- il) - [5- (1H-pyrazol-4-yl) -thiophene-3-ii] -metanone 3, 3-disubstituted and (piperidin-1-yl) - [5- (1 H -pyrazol-4-yl) -thiophene-3-ii] -4,4-disubstituted methanone of the following Formula (I) which, among other things, inhibit 11β dehydrogenase -hydroxysteroid type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and to the use of such compounds and compositions, both In Vitro and in vivo, to inhibit 11β-hydroxysteroid type 1 dehydrogenase; to treat disorders that are enhanced by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. |